Evidence map›Paper›PMID 41170356›Full record

ReviewFrontiers in nutrition2025

Natural compounds regulating fatty acid oxidation in the treatment of diabetic kidney disease.

Jianing Sun, Chengqian Yin, Zhe Li, Xiangyu Gao, Songlin Li, Hua Gao, Yan An, Peng Liu, Na Liu

Abstract readReview
In one paragraph

Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jianing Sun *Renal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Chengqian Yin *Renal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Zhe Li *Renal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Xiangyu GaoRenal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Songlin LiRenal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Hua GaoRenal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Yan AnRenal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Peng LiuXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Na LiuRenal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic kidney disease (DKD) is one of the leading causes of end-stage renal disease worldwide, and lipid metabolism disorder is a key factor in accelerating its progression. Among them, the impaired fatty acid oxidation (FAO) function of renal tissue constitutes one of the core pathological links of lipid metabolism disorders. In DKD, impaired FAO function can directly lead to lipid accumulation, mitochondrial stress, and trigger an inflammatory cascade, thereby promoting the occurrence and development of glomerulosclerosis and renal tubular injury. However, the efficacy of current DKD treatment strategies is still limited. Natural compounds (such as polyphenols, phenolic acids, alkaloids, glycosides, and carotenoids) have shown potential in renal protection due to their multi-target and multi-pathway characteristics. Studies have shown that regulating the FAO process in the context of lipid metabolism disorders is a crucial mechanism by which natural compounds can exert anti-DKD effects. It is worth noting that peroxisome proliferator-activated receptors (PPARs) are core transcription factors that regulate FAO. Specifically, these active ingredients can upregulate the expression of their downstream target genes by activating the PPAR signaling pathway (especially PPARα), thereby improving FAO function, correcting abnormal lipid metabolism, and ultimately delaying the progression of renal pathological mechanisms such as inflammation and fibrosis. The above findings provide an essential scientific basis for the development of new, safe, and effective DKD therapeutic drugs.

Indexed as

diabetic kidney diseasefatty acid oxidationnatural compoundsPPARsrenal lipid metabolism disorders

Identifiers

PMID41170356
PMCPMC12568393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.